Research
5 articles

Industry
Treating the Disease or Opening a Learning Window? What a New Review of Psychedelics for Substance Use Disorders Means for Canadian Practitioners
A new Yale and WashU review asks whether psychedelics treat substance use disorders or open a window for learning. What it means for Canadian practitioners.

Industry
One Nasal Dose, Two Hours in Clinic: What the New JAMA Mebufotenin Trial Means for Canadian Practitioners
A JAMA phase 2b trial links one intranasal dose of mebufotenin (5-MeO-DMT) to lower depression scores in TRD. What it means for Canadian clinicians.

Industry
'The Start of a Process, Not the Cure': What Psychedelic Trial Participants Want Practitioners to Know
A new Frontiers in Psychiatry study asked former psychedelic trial participants what helped and what hurt. Key lessons for Canadian practitioners.

Industry
One Session, One Year of Follow-Up: What a Swedish Trial Tells Practitioners About Durability
A Swedish randomized trial followed participants for a full year after a single psychedelic therapy session. What it means for practitioners.

Industry
Three Psychedelics, One Shared Brain Signature: What a New Stanford Study Means for Practitioners
A Stanford-led PNAS study looks at how psychedelics affect signalling into the brain's default mode network. What it means for practitioners.